Close
Achema middle east
swop processing & packaging

Otsuka Holdings Announces New, Additional Certification Under “ISO 22301” (International Standard for Business Continuity Management)

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Expands scope of certification to include additional Otsuka Group products, reflecting the company’s improved resiliency and continuous operational capability during unexpected events.

Otsuka Holdings Co Ltd is pleased to announce that its subsidiary Taiho Pharmaceutical Co., Ltd. was granted the ISO 22301*1 certification, the international standard for business continuity management (BCM) for “the stable supply of anticancer drugs”, by BSI Japan*2 , on May 16, 2016. The ISO 22301 certification validates the maturity of an organization’s BCM program, confirming that all corresponding activities are implemented in a controlled manner to build the capability to respond to business interruptions.

The business continuity initiatives carried out in each of the Group companies have been reviewed internally and Otsuka Holdings together with the Group companies have built a group-wide system to advance business continuity management.

The Otsuka Group acquired ISO 22301 certification in August 2012 for the production and stable supply of medicinal products, beverages, and foods by the subsidiary Otsuka Pharmaceutical. In April 2015 the scope was expanded to include certification for the stable supply of intravenous solutions. Now certification has been expanded to include medicinal products from the subsidiary Taiho Pharmaceutical.

The Otsuka Group will continue to advance BCP efforts in cooperation with the Group companies such as Otsuka Pharmaceutical, Otsuka Pharmaceutical Factory, Taiho Pharmaceutical and Otsuka Warehouse to ensure stable supply of Otsuka Group products during and after unexpected events.

Glossary *1) ISO22301 (full name: “ISO 22301:2012 Societal security — Business continuity management systems — Requirements”) is the new international standard for business continuity management, published by the International Organization for Standardization (ISO) in May 2012. ISO22031 provides a forma business continuity framework to enable any organization to build capabilities to minimize the impact of disruptions so that it keeps business running during and following a disruption. *2) BSI( British Standards Institution) is the world’s first national standards body and was instrumental in the formation of ISO, the International Organization for Standardization. Since its establishment in 1901, BSI has been a leading global provider of standards. Many ISO Standards have their origin in British Standards developed by BSI. BSI Group Japan is BSI’s Japanese subsidiary and was established in 1999. BSI Japan is a leading certification body in Japan.

Profile of Otsuka Holdings Co., Ltd.
Established : July 8, 2008
Capital : 81,690 million yen
President : Tatsuo Higuchi, president and representative director, CEO
Head Office : 2-9, Kanda-Tsukasamachi, Chiyoda-ku, 101-0048 Tokyo, Japan
Employees : 78 (as of December 31, 2015)
Business Description : Holding company

Latest stories

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »